Medication Safety During Ovarian Tissue Preservation: A Comprehensive Clinical Review

Abstract

Ovarian tissue preservation has emerged as a pivotal fertility-preserving strategy for women at risk of premature ovarian insufficiency due to medical treatments such as chemotherapy or radiotherapy. As this technique gains traction in the field of reproductive medicine, the safety of pharmacological agents used during the peri-procedural period is of paramount importance. This review synthesizes the current evidence on medication safety during ovarian tissue preservation, delineating the epidemiological context, pathophysiological mechanisms, risk factors, clinical features, diagnostic considerations, management strategies, recent advances, guideline recommendations, and practical implications for clinicians. The discussion integrates recent guideline updates and focuses on optimizing outcomes while minimizing risks associated with medication exposure.

Introduction

Ovarian tissue preservation (OTP) has become increasingly relevant in oncofertility and reproductive endocrinology, particularly for young women with malignancies or other conditions threatening ovarian function. The procedure entails the surgical removal and cryopreservation of ovarian cortical tissue, which can later be reimplanted to restore fertility or endocrine function. Ensuring the safety of medications administered before, during, and after tissue procurement is critical, as certain pharmacological agents may compromise ovarian viability, follicular integrity, or increase perioperative risks. This review critically examines the evidence on medication safety in OTP, aiming to equip clinicians with a thorough understanding necessary for safe, evidence-based patient care.

Epidemiology / Disease Burden

The global burden of cancer and autoimmune diseases in reproductive-aged women underscores the importance of fertility preservation strategies. Epidemiological data indicate that over 1.5 million women under 40 are diagnosed with cancer annually worldwide, with a significant proportion requiring gonadotoxic treatments. Advances in cancer therapy have improved survival, but also increased the cohort of long-term survivors facing infertility. Ovarian tissue cryopreservation is indicated in prepubertal girls and women for whom oocyte or embryo freezing is not feasible, expanding the population potentially exposed to perioperative medications with unestablished safety profiles in this context.

Pathophysiology

The ovarian cortex harbors primordial follicles essential for future fertility. During OTP, surgical and anesthetic interventions, as well as perioperative medications, may affect the tissue's microenvironment. Mechanisms of potential harm include direct cytotoxicity (e.g., certain chemotherapeutics), ischemia-reperfusion injury, and oxidative stress. Medications influencing vascular tone, inflammation, and coagulation can further modulate tissue survival post-thaw. Understanding these mechanisms is crucial for risk stratification and the selection of safe pharmacological regimens during OTP procedures.

Risk Factors

Several factors increase the risk of adverse medication effects during OTP. These include prior exposure to gonadotoxic agents, underlying medical comorbidities (such as coagulopathies or hepatic dysfunction), concurrent use of nephrotoxic or hepatotoxic drugs, and genetic susceptibility to drug metabolism variations. Surgical risk factors include prolonged ischemia time and suboptimal tissue handling, which can amplify medication-induced harm. Patient-specific risk assessment is essential to minimize complications and optimize tissue viability.

Clinical Features

While OTP is generally well-tolerated, clinicians must monitor for features suggestive of medication-related complications. These may include delayed wound healing, perioperative bleeding, infection, or signs of tissue necrosis. Adverse reactions to anesthetics and analgesics, such as hypersensitivity or respiratory depression, also warrant vigilance. Long-term, the most critical feature is the functional integrity of the preserved tissue, assessed by restoration of endocrine function and fertility post-reimplantation.

Diagnosis

Diagnosis of medication-induced complications during OTP relies on clinical assessment, laboratory investigation, and imaging. Biomarkers of ovarian reserve (e.g., anti-Müllerian hormone, follicle count) are monitored pre- and post-procedure. In cases of suspected adverse drug reactions, liver and renal function tests, coagulation profiles, and inflammatory markers may be informative. Imaging modalities such as ultrasound or MRI can identify hematoma, infection, or compromised tissue perfusion.

Treatment & Management

Optimal management involves meticulous preoperative planning, including medication reconciliation and risk assessment. Non-essential medications with known ovarian toxicity should be withheld. Anesthetic agents with minimal ovarian impact, such as propofol and sevoflurane, are preferred over those with theoretical cytotoxicity. Perioperative antibiotics should be selected for efficacy and safety, avoiding agents with potential gonadotoxic effects (e.g., high-dose aminoglycosides). Pain management should prioritize non-opioid options when feasible, balancing efficacy with safety. In cases of suspected medication-related complications, prompt withdrawal of the offending agent, supportive care, and specialist consultation are indicated.

Recent Advances / Emerging Therapies

Recent years have witnessed significant progress in the development of safer pharmacological adjuncts for OTP. Antioxidant therapies, such as melatonin and coenzyme Q10, have shown promise in reducing oxidative damage during tissue handling and cryopreservation. Novel approaches to ischemia mitigation, such as ischemic preconditioning and the use of vasoactive agents, are under investigation. Pharmacogenomics is emerging as a tool to personalize medication selection and dosing, minimizing adverse effects based on individual genetic profiles. Furthermore, advanced tissue culture systems and vitrification protocols may allow for reduced reliance on potentially harmful medications.

Guideline Recommendations

International guidelines from organizations such as the American Society for Reproductive Medicine (ASRM) and the European Society of Human Reproduction and Embryology (ESHRE) emphasize the importance of multidisciplinary collaboration in OTP. Recommendations include thorough medication review, avoidance of unnecessary exposure to known gonadotoxins, and the use of evidence-based anesthetic and perioperative drug protocols. Guidelines also advocate for ongoing research and pharmacovigilance to enhance understanding of medication safety in this rapidly evolving field. Shared decision-making with patients, informed by the latest evidence, remains a cornerstone of best practice.

Conclusion

Medication safety is a critical determinant of success in ovarian tissue preservation. Clinicians must integrate epidemiological data, pathophysiological insights, risk stratification, and guideline-based recommendations to optimize outcomes for patients undergoing OTP. Ongoing research into the mechanisms of medication-induced ovarian injury and the development of safer pharmacological adjuncts promises to further enhance the safety and efficacy of this fertility-preserving intervention. Rigorous adherence to evidence-based protocols and individualized patient care will ensure that OTP continues to be a viable and safe option for women facing gonadotoxic treatments.